Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KALV

KalVista Pharmaceuticals Inc

Dec 12 • 02:39PM ET

8.60

Dollar change -0.49
Percentage change -5.39	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE RARE CORT QURE VKTX VSTM PIRS LPTX XERS XBIO

| Held by: VTI IWM VXF XBI IWO IBB VTWO DFAS IWC DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.64	Insider Own	29.83%	Shs Outstand	43.27M	Perf Week	-5.02%
Market Cap	425.00M	Forward P/E	-	EPS next Y	-2.55	Insider Trans	-0.55%	Shs Float	34.68M	Perf Month	-19.40%
Income	-156.39M	PEG	-	EPS next Q	-0.88	Inst Own	74.28%	Short Float	20.93%	Perf Quarter	-22.80%
Sales	0.00M	P/S	-	EPS this Y	-6.01%	Inst Trans	5.60%	Short Ratio	17.74	Perf Half Y	-29.85%
Book/sh	3.10	P/B	2.78	EPS next Y	30.12%	ROA	-104.41%	Short Interest	7.26M	Perf Year	-11.89%
Cash/sh	2.75	P/C	3.13	EPS next 5Y	-	ROE	-125.90%	52W Range	8.19 - 16.88	Perf YTD	-29.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.06%	ROI	-112.78%	52W High	-49.05%	Beta	0.83
Dividend TTM	-	Quick Ratio	6.87	Sales past 5Y	-24.26%	Gross Margin	-	52W Low	5.01%	ATR (14)	0.63
Dividend Ex-Date	-	Current Ratio	6.87	EPS Y/Y TTM	-19.16%	Oper. Margin	-	RSI (14)	35.52	Volatility	7.12% 6.38%
Employees	150	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	26.40
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-13.16%	Payout	-	Rel Volume	0.62	Prev Close	9.09
Sales Surprise	-	EPS Surprise	-0.22%	Sales Q/Q	-	Earnings	Dec 05 BMO	Avg Volume	409.31K	Price	8.60
SMA20	-9.98%	SMA50	-19.84%	SMA200	-27.30%	Trades		Volume	202,595	Change	-5.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-15-20	Initiated	H.C. Wainwright	Buy	$30
Jul-29-19	Initiated	SVB Leerink	Outperform	$31
Mar-20-19	Initiated	Needham	Buy	$35
Oct-30-18	Initiated	Jefferies	Buy	$30
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-31-17	Initiated	BTIG Research	Buy	$18

Dec-05-24 06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-24 07:00AM	KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors (Business Wire)
Nov-12-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-05-24 07:29AM	KalVista Secures $184M Financing for Sebetralstat Launch (TipRanks)
06:30AM	Loading…
06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-04-24 07:05AM	KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million (Business Wire) +9.61%
07:00AM	KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust (Business Wire)
Oct-28-24 06:30AM	KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology (Business Wire)
Oct-18-24 06:30AM	KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) (Business Wire)
Oct-04-24 12:29PM	KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum (Business Wire)
Oct-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 06:30AM	KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -6.16%
Sep-26-24 06:30AM	KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) (Business Wire) +5.71%
Sep-10-24 07:00AM	KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (Business Wire) -5.56%
06:30AM	Loading…
06:30AM	KalVista Appoints Brian Piekos as Chief Financial Officer (Business Wire)
Sep-06-24 06:30AM	KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 (Business Wire)
Sep-05-24 06:30AM	KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update (Business Wire)
Sep-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-03-24 06:30AM	KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema (Business Wire) -7.62%
Aug-29-24 06:30AM	KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium (Business Wire)
Aug-15-24 06:30AM	KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema (Business Wire)
Aug-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-11-24 02:52PM	KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 (InvestorPlace)
06:30AM	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results (Business Wire)
Jul-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 06:30AM	KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11 (Business Wire) +6.54%
Jun-18-24 06:30AM	KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema (Business Wire)
Jun-06-24 06:30AM	KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024 (Business Wire)
Jun-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
06:30AM	Loading…
Jun-03-24 06:30AM	KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 (Business Wire)
May-31-24 04:09PM	KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema (Business Wire)
May-24-24 06:30AM	KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024 (Business Wire)
May-21-24 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
May-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-01-24 06:30AM	KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year (Business Wire) +7.31%
Apr-22-24 06:30AM	KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors (Business Wire)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 06:30AM	KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-18-24 06:30AM	KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas (Business Wire)
Mar-12-24 06:30AM	KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat (Business Wire)
Mar-11-24 06:30AM	KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update (Business Wire) -8.77%
Mar-08-24 06:30AM	KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas (Business Wire)
Mar-07-24 06:30AM	KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer (Business Wire)
Mar-06-24 06:30AM	KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference (Business Wire)
Mar-04-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-24 06:30AM	KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire) +6.79%
Feb-26-24 06:30AM	KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire) +8.82%
Feb-20-24 06:30AM	KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat (Business Wire) -7.13%
Feb-16-24 06:30AM	KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-15-24 06:30AM	KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-14-24 04:18PM	KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Feb-13-24 07:10AM	UPDATE 1-KalVista meets main goals in late-stage trial for genetic disease (Reuters) -7.42%
06:40AM	KalVista meets main goals in late-stage trial for skin condition treatment (Reuters)
06:30AM	KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema (Business Wire)
01:30AM	Kalvista pill succeeds in late-stage study for rare swelling disorder (BioPharma Dive)
Feb-02-24 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-01-24 12:02PM	Hedge Fund and Insider Trading News: David Einhorn, Crispin Odey, Bill Ackman, Stanley Druckenmiller, Ken Griffin, Burke Herbert Financial Services (BHRB), KalVista Pharmaceuticals, Inc. (KALV), and More (Insider Monkey)
Jan-13-24 03:12AM	Insider Sell: Chief Scientific Officer Edward Feener Sells 22,679 Shares of KalVista ... (GuruFocus.com)
Jan-12-24 03:03AM	Insider Sell: Chief Scientific Officer Edward Feener Sells 17,321 Shares of KalVista ... (GuruFocus.com)
Dec-30-23 09:02AM	Insider Sell: CEO Thomas Crockett Sells 30,000 Shares of KalVista Pharmaceuticals Inc (KALV) (GuruFocus.com)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-20-23 06:30AM	KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology (Business Wire)
Dec-07-23 04:49PM	KalVista Pharmaceuticals Inc (KALV) Reports Second Fiscal Quarter Results (GuruFocus.com) -9.03%
06:30AM	KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update (Business Wire)
Dec-05-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-23-23 05:14AM	Insider Sell Alert: CEO Thomas Crockett Offloads Shares of KalVista Pharmaceuticals Inc (GuruFocus.com)
Nov-22-23 05:04AM	Insider Sell Alert: KalVista Pharmaceuticals Inc's Benjamin Palleiko Sells 13,008 Shares (GuruFocus.com)
Nov-14-23 10:31PM	3 Micro-Cap Stocks That Could Be Moonshots (InvestorPlace)
06:30AM	KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (Business Wire)
Nov-13-23 06:30AM	KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved (Business Wire)
Nov-07-23 06:30AM	KalVista Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-02-23 06:30AM	KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (Business Wire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-25-23 09:40AM	Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? (Zacks) -6.71%
Oct-24-23 06:30AM	KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference (Business Wire)
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks)
Oct-03-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-20-23 09:02AM	Is it a Good Idea to Invest in KalVista (KALV) Stock Now? (Zacks)
Sep-19-23 06:30AM	KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference (Business Wire)
Sep-18-23 08:52AM	5 Stocks to Buy as Drug Industry Displays Strong Fundamentals (Zacks)
Sep-14-23 01:04AM	Insider Sell: Director Albert Cha Sells 18,000 Shares of KalVista Pharmaceuticals Inc (GuruFocus.com)
Sep-07-23 06:30AM	KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update (Business Wire)
Sep-06-23 09:40AM	Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-28-23 06:30AM	KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA (Business Wire)
Aug-02-23 04:15PM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-25-23 06:30AM	KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Nicole Sweeny as Chief Commercial Officer (Business Wire)
Jul-24-23 06:30AM	KalVista Pharmaceuticals Presents New HAE Attack Journey Data at 2023 US HAEA National Summit (Business Wire)
Jul-14-23 06:30AM	KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit (Business Wire)
Jul-10-23 09:54AM	KalVista (KALV) Surges 15% on Update From Angioedema Study (Zacks)
Jul-07-23 06:30AM	KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results (Business Wire) +14.97%
Jul-05-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-12-23 06:30AM	KalVista Pharmaceuticals Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology (Business Wire)
Jun-05-23 06:30AM	KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-02-23 06:30AM	KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) (Business Wire)
May-31-23 06:30AM	KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference (Business Wire)
May-23-23 06:30AM	KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference (Business Wire)
May-08-23 06:30AM	KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop (Business Wire)

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Dec 09 '24	Sale	9.75	7,627	74,363	274,596	Dec 09 09:08 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 26 '24	Sale	9.87	2,187	21,586	97,012	Nov 27 08:45 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 26 '24	Sale	9.87	1,963	19,378	91,142	Nov 27 08:43 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Nov 18 '24	Sale	9.26	14,400	133,294	266,598	Nov 19 07:19 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Nov 18 '24	Sale	9.26	7,192	66,573	89,980	Nov 19 07:18 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Nov 18 '24	Sale	9.26	8,077	74,766	94,199	Nov 19 07:18 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Sep 09 '24	Sale	12.19	7,352	89,622	250,800	Sep 10 08:31 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 23 '24	Sale	12.40	2,135	26,474	83,745	Aug 26 08:00 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 23 '24	Sale	12.40	1,916	23,758	85,676	Aug 26 07:58 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Aug 19 '24	Sale	12.01	7,973	95,782	80,880	Aug 21 09:26 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Aug 19 '24	Sale	12.01	14,215	170,769	242,527	Aug 21 09:25 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Aug 19 '24	Sale	12.01	7,102	85,318	84,467	Aug 21 09:25 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	Jun 07 '24	Sale	11.53	7,465	86,068	224,547	Jun 10 06:42 PM
Feener Edward P.	CHIEF SCIENTIFIC OFFICER	May 20 '24	Sale	11.76	8,088	95,151	72,858	May 21 05:59 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	May 20 '24	Sale	11.76	13,175	154,997	70,325	May 21 05:58 PM
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER	May 20 '24	Sale	11.76	21,959	258,337	216,387	May 21 05:57 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	May 20 '24	Sale	11.76	11,610	136,586	80,074	May 21 05:55 PM
Feener Edward P.	CHIEF SCIENTIFIC OFFICER	Feb 20 '24	Sale	14.07	28,288	397,929	62,157	Feb 21 09:51 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 20 '24	Sale	14.11	12,053	170,124	72,895	Feb 21 09:48 PM
Palleiko Benjamin L	CFO, CBO	Feb 20 '24	Sale	14.11	22,802	321,846	187,315	Feb 21 09:46 PM
Audhya Paul K.	CHIEF MEDICAL OFFICER	Feb 20 '24	Sale	14.12	14,295	201,774	52,886	Feb 21 09:44 PM
Crockett Thomas Andrew	CEO	Feb 20 '24	Sale	14.11	24,888	351,289	211,203	Feb 21 09:41 PM
Palleiko Benjamin L	CFO, CBO	Feb 14 '24	Sale	15.01	40,855	613,205	159,088	Feb 16 04:21 PM
Crockett Thomas Andrew	CEO	Feb 14 '24	Sale	15.01	58,356	875,883	181,676	Feb 16 04:20 PM
Feener Edward P.	CHIEF SCIENTIFIC OFFICER	Feb 14 '24	Sale	15.01	28,171	422,827	71,657	Feb 16 04:19 PM
Yea Christopher	CHIEF DEVELOPMENT OFFICER	Feb 14 '24	Sale	15.01	39,886	598,661	66,160	Feb 16 04:18 PM
Venrock Healthcare Capital Par	10% Owner	Feb 07 '24	Buy	14.56	51,827	754,601	4,794,984	Feb 08 08:11 PM
Venrock Healthcare Capital Par	10% Owner	Feb 08 '24	Buy	14.70	29,747	437,281	4,824,731	Feb 08 08:11 PM
Venrock Healthcare Capital Par	10% Owner	Feb 06 '24	Buy	14.74	4,474	65,947	4,743,157	Feb 08 08:11 PM
Crockett Thomas Andrew	CEO	Feb 01 '24	Sale	16.22	10,000	162,198	117,532	Feb 05 05:55 PM
Venrock Healthcare Capital Par	10% Owner	Jan 30 '24	Buy	14.47	88,099	1,274,793	4,738,683	Feb 01 04:38 PM
Venrock Healthcare Capital Par	10% Owner	Jan 29 '24	Buy	14.22	80,600	1,146,132	4,650,584	Jan 29 07:07 PM
Venrock Healthcare Capital Par	10% Owner	Jan 25 '24	Buy	12.73	7,030	89,492	4,565,810	Jan 29 07:07 PM
Venrock Healthcare Capital Par	10% Owner	Jan 26 '24	Buy	12.98	4,174	54,179	4,569,984	Jan 29 07:07 PM
Venrock Healthcare Capital Par	10% Owner	Jan 22 '24	Buy	12.55	67,546	847,702	4,527,197	Jan 24 08:24 PM
Venrock Healthcare Capital Par	10% Owner	Jan 24 '24	Buy	12.44	20,686	257,334	4,558,780	Jan 24 08:24 PM
Venrock Healthcare Capital Par	10% Owner	Jan 23 '24	Buy	12.54	10,897	136,648	4,538,094	Jan 24 08:24 PM
Venrock Healthcare Capital Par	10% Owner	Jan 17 '24	Buy	12.60	78,925	994,455	4,394,971	Jan 19 06:02 PM
Venrock Healthcare Capital Par	10% Owner	Jan 18 '24	Buy	12.51	39,680	496,397	4,434,651	Jan 19 06:02 PM
Venrock Healthcare Capital Par	10% Owner	Jan 19 '24	Buy	12.43	25,000	310,750	4,459,651	Jan 19 06:02 PM
Venrock Healthcare Capital Par	10% Owner	Jan 16 '24	Buy	12.73	19,599	249,495	4,316,046	Jan 16 07:04 PM
Venrock Healthcare Capital Par	10% Owner	Jan 11 '24	Buy	12.68	6,647	84,284	4,296,447	Jan 16 07:04 PM
Feener Edward P.	Chief Scientific Officer	Jan 11 '24	Sale	13.03	22,679	295,514	39,828	Jan 12 04:26 PM
Venrock Healthcare Capital Par	10% Owner	Jan 08 '24	Buy	12.44	69,184	860,649	4,221,284	Jan 10 08:57 PM
Venrock Healthcare Capital Par	10% Owner	Jan 10 '24	Buy	12.67	47,700	604,359	4,289,800	Jan 10 08:57 PM
Venrock Healthcare Capital Par	10% Owner	Jan 09 '24	Buy	12.56	20,816	261,449	4,242,100	Jan 10 08:57 PM
Feener Edward P.	Chief Scientific Officer	Jan 08 '24	Sale	13.01	17,221	224,000	62,607	Jan 10 06:05 PM
Feener Edward P.	Chief Scientific Officer	Jan 09 '24	Sale	13.00	100	1,300	62,507	Jan 10 06:05 PM
Venrock Healthcare Capital Par	10% Owner	Jan 04 '24	Buy	12.11	41,764	505,762	4,152,100	Jan 05 04:13 PM
Venrock Healthcare Capital Par	10% Owner	Jan 03 '24	Buy	12.20	17,605	214,781	4,110,336	Jan 05 04:13 PM
Venrock Healthcare Capital Par	10% Owner	Dec 28 '23	Buy	12.50	471,490	5,893,625	4,086,718	Dec 29 06:44 PM
Venrock Healthcare Capital Par	10% Owner	Dec 27 '23	Buy	11.97	41,514	496,923	3,615,228	Dec 29 06:44 PM
Venrock Healthcare Capital Par	10% Owner	Dec 29 '23	Buy	12.49	6,013	75,102	4,092,731	Dec 29 06:44 PM
Crockett Thomas Andrew	CEO	Dec 27 '23	Sale	12.02	30,000	360,453	127,532	Dec 28 04:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KALV

KalVista Pharmaceuticals Inc

Upgrade your FINVIZ experience